Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 13,30€(+58,71%). Der Median liegt bei 14,90€(+77,80%).
Kaufen | 11 |
Halten | 4 |
Verkaufen | 0 |
Scoring-Modelle
Dividenden-Strategie | 8 / 15 |
HGI-Strategie | 6 / 18 |
Levermann-Strategie | 4 / 13 |
News
Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)
HONG KONG , June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will be presented at the 85th Scientific Sessions of American Diabetes Association (ADA) in Chicago, U.S. Details of the Poster Presentations Poster Number: 750-P Abstract Title: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) Poster Number: 847-P Abstract Title: ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e.» Mehr auf prnewswire.com
Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints
Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary endpoints Denifanstat demonstrated a favorable safety and tolerability profile Denifanstat was 98% and 178% more effective than U.S. Food and Drug Administration (FDA)-approved sarecycline and doxycycline with regard to placebo-adjusted percent treatment success, respectively, 18.6% for denifanstat versus 9.4% for sarecycline, 18.6% versus 6.7% for doxycycline Denifanstat was 60% more effective than FDA-approved clascoterone cream with regard to placebo-adjusted percent treatment success, 18.6% for denifanstat versus 11.6% for clascoterone cream, respectively The exceptional efficacy of denifanstat coupled with its favorable safety profile in the Phase III trial provides a potential major break-through for the treatment of acne HONG KONG , June 3, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) inhibitor, meets all primary, key secondary, and secondary endpoints in the Phase III clinical trial for the treatment of moderate to severe acne vulgaris (NCT06192264). The Phase III clinical trial was a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of denifanstat once-daily oral tablet in 480 patients with moderate to severe acne vulgaris.» Mehr auf prnewswire.com
Investors Heavily Search Ardmore Shipping Corporation (ASC): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Ardmore Shipping (ASC). This makes it worthwhile to examine what the stock has in store.» Mehr auf zacks.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 68,40 Mio | 30,56% |
Bruttoeinkommen | 19,42 Mio | 56,02% |
Nettoeinkommen | 5,78 Mio | 84,10% |
EBITDA | 13,70 Mio | 69,98% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 342,87 Mio€ |
Anzahl Aktien | 40,62 Mio |
52 Wochen-Hoch/Tief | 20,30€ - 7,29€ |
Dividendenrendite | 10,41% |
Dividenden TTM | 0,88€ |
Nächste Dividende | 0,0438€ |
Beta | 0,01 |
KGV (PE Ratio) | 4,17 |
KGWV (PEG Ratio) | −0,14 |
KBV (PB Ratio) | 0,61 |
KUV (PS Ratio) | 1,31 |
Unternehmensprofil
Ardmore Shipping Corporation befasst sich mit dem weltweiten Seetransport von Erdölprodukten und Chemikalien. Am 15. Februar 2022 betrieb das Unternehmen eine Flotte von 25 Doppelhüllen-Produkt- und Chemikalientankern. Es bedient Ölkonzerne, Ölgesellschaften, Öl- und Chemikalienhändler, Chemieunternehmen und Pooling-Dienstleister. Das Unternehmen wurde im Jahr 2010 gegründet und hat seinen Sitz in Pembroke, Bermuda.
Name | Ardmore Shipping |
CEO | Gernot Ruppelt |
Sitz | Pembroke, Irland |
Website | |
Industrie | Seetransport |
Börsengang | |
Mitarbeiter | 56 |
Ticker Symbole
Börse | Symbol |
---|---|
NYSE | ASC |
Frankfurt | A61.F |
Düsseldorf | A61.DU |
München | A61.MU |
Assets entdecken
Shareholder von Ardmore Shipping investieren auch in folgende Assets